Pricing Log in Create free account

Mineralys Therapeutics, Inc. (MLYS) vs Ocular Therapeutix, Inc. (OCUL)

Mineralys Therapeutics, Inc. and Ocular Therapeutix, Inc. are both Biotechnology companies. Mineralys Therapeutics, Inc. and Ocular Therapeutix, Inc. are of similar size ($1.4B and $1.4B). Mineralys Therapeutics, Inc. has the higher net margin (0.00% vs −579.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Mineralys Therapeutics, Inc. leads on 7 and Ocular Therapeutix, Inc. on 5.

Valuation

Metric MLYS OCUL Biotechnology median
P/E n/m n/m 10.60
P/S n/m 28.61 9.40
P/B 2.36 2.86 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 18.51 9.02
Earnings yield (27.62%) (21.45%) (32.88%)
Free cash flow yield (10.68%) (17.13%) (23.13%)

Profitability

Metric MLYS OCUL Biotechnology median
Gross margin — 87.11% 68.51%
Operating margin 0.00% (603.04%) 0.00%
Net margin 0.00% (579.10%) 0.00%
Free cash flow margin 0.00% (490.07%) 0.00%
Return on equity (80.88%) (72.99%) (51.96%)
Return on assets (69.67%) (53.70%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric MLYS OCUL Biotechnology median
Revenue growth (TTM) — (8.14%) 6.76%
EPS growth (last fiscal year) 37.43% (16.39%) 29.88%
Revenue growth, 5-year CAGR — 24.45% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MLYS OCUL Biotechnology median
Debt to equity 0.18 0.14 0.00
Current ratio 34.46 13.11 4.97
Net debt to EBITDA 3.85 2.51 1.01

Dividend

Metric MLYS OCUL Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric MLYS OCUL Biotechnology median
Market cap 1.35b 1.41b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack